Temozolomide in combination with fotemustine in patients with metastatic melanoma

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 2, 2008, Pages 293-298

  Tas, Faruk ^a   Camlica, Hakan ^a   Topuz, Erkan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Fotemustine; Melanoma; Metastatic; Temozolomide

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; DEXAMETHASONE; FOTEMUSTINE; GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN ANTAGONIST; TEMOZOLOMIDE;

ADJUVANT THERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS;

EID: 43749115804     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0606-5     Document Type: Article

References (20)

1. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648
2. Li Y, McClay EF (2002) Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol 29:413-426
3. Balch CM, Atkins MB, Sober AJ (2005) Cutaneous melanoma. In: Devita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. Lippincott Williams and Wilkins, Philadelphia, pp 1754-1809
4. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al (1999) Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17:2745-2751
5. Middleton MR, Lorigan P, Owen J, Ashcoft L, Lee SM, Harper P, et al (2000) A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 82:1158-1162
6. Newlands ES, Stevens HF, Wedge SR, Wheelhouse RT, Brock C (1997) Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23:35-61
7. Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS, et al (1992) Phase I trial of temozolomide. Br J Cancer 65:287-291
8. Bleehan NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH, et al (1995) Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 13:910-913
9. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158-166
10. Bafaloukos D, Gogas H, Georgoulias V, Briassoulis E, Fountzilas G, Samantas E, et al (2002) Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol 20:420-425
11. Hwu WJ, Krown SE, Menell JH, Panageas KS, Merrell J, Lamb LA, et al (2003) Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 21:3351-3356
12. Danson S, Lorigan P, Arance A, Clamp A, Ranson M, Hodgetts J, et al (2003) Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol 21:2551-2557
13. Tas F, Argon A, Camlica H, Topuz E (2005) Temozolomide in combination with cisplatin in patients with metastatic melanoma: a phase II trial. Melanoma Res 15(6):543-548
14. 6-Alkylguanine-DNA-Alkyltransferase. Clin Cancer Res 7:2309-2317
15. 6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88:1004-1011
16. Marzolini C, Decosterd L, Shen F, Gander M, Leyvraz S, Bauer J, et al (1998) Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. Cancer Chemother Pharmacol 42:433-440
17. 6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. Ann Oncol 10:831-838
18. Aamdal S, Gerard B, Bohman T, D'Incalci M (1992) Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma-an effective combination with unexpected toxicity. Eur J Cancer 28:447-450
19. Lee SM, Margison GP, Woodcock AA, Thatcher N (1993) Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignat melanoma. Br J Cancer 67:1356-1360
20. Plowman J, Waud WR, Koutsoukos AD, Rubinstein LV, Moore TD, Grever MR (1994) Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumour xenographs and synergism with 1,3-bis(2-chloroethyl)-1-nitro- sourea. Cancer Res 54:3793-3799